Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Omalizumab-igec
Generic Name
Omalizumab-igec
Active Ingredient
OmalizumabCategory
Anti-IgE [EPC]
Variants
3
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Omalizumab-igec, you must consult a qualified healthcare professional.
Detailed information about Omalizumab-igec
Omalizumab is a recombinant DNA-derived monoclonal antibody that selectively binds to human immunoglobulin E (IgE), used as a maintenance treatment for moderate-to-severe persistent asthma, chronic spontaneous urticaria, and IgE-mediated food allergies.
Dosage for omalizumab is highly individualized and varies significantly depending on the condition being treated. For Chronic Spontaneous Urticaria (CSU), the standard adult dose is either 150 mg or 300 mg administered subcutaneously every 4 weeks. The 300 mg dose is frequently preferred for its superior efficacy in clinical trials.
For Allergic Asthma, Nasal Polyps, and Food Allergies, the dosage is determined by a combination of the patient's body weight (kg) and their baseline total serum IgE level (IU/mL), measured before the start of treatment. Doses range from 75 mg to 600 mg, administered either every 2 weeks or every 4 weeks. For example, a patient weighing 70 kg with an IgE level of 300 IU/mL might require 300 mg every 2 weeks. Your healthcare provider will use a standardized dosing chart provided by the manufacturer to calculate your specific requirement.
Omalizumab is approved for pediatric use in specific age brackets:
It is not currently approved for children under 1 year of age for food allergies or under 6 years of age for asthma. Pediatric patients must be monitored closely for growth and developmental milestones during long-term biologic therapy.
No formal studies have been conducted in patients with renal impairment. However, since monoclonal antibodies are primarily cleared via intracellular catabolism rather than renal filtration, dose adjustments are generally not expected to be necessary. Healthcare providers will monitor these patients based on clinical response.
No studies have been performed in patients with hepatic impairment. While the reticuloendothelial system in the liver is involved in IgG clearance, the impact of liver disease on omalizumab pharmacokinetics is unknown. Caution and close clinical monitoring are advised.
Clinical trials did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function.
Omalizumab is administered by subcutaneous (SC) injection into the thigh, abdomen, or upper arm.
If you miss a dose of omalizumab, contact your healthcare provider immediately to reschedule. It is important to maintain a consistent dosing schedule to keep IgE levels suppressed. Do not 'double up' on doses to make up for a missed one. If you are self-administering at home and realize you missed a dose, call your clinic for guidance on when to resume your schedule.
The maximum tolerated dose of omalizumab has not been determined. In clinical trials, single doses up to 4,000 mg were administered without evidence of dose-limiting toxicity. However, if an overdose is suspected, the patient should be monitored for any signs or symptoms of adverse reactions, and appropriate symptomatic treatment should be instituted immediately. Contact a Poison Control Center or emergency services if a significant dosing error occurs.
> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or frequency without medical guidance. This medication is a long-term maintenance therapy and must be taken regularly even if you feel well.
In clinical trials, the most frequently reported side effects associated with omalizumab involve the site of administration and general respiratory symptoms. These include:
Omalizumab is a potent biologic medication that requires careful medical supervision. It is not intended for the treatment of acute asthma symptoms, such as sudden shortness of breath or status asthmaticus. Patients must continue to have their 'rescue' inhalers (like albuterol) available at all times. Furthermore, omalizumab should not be used to treat other forms of hives that are not 'spontaneous' (such as hives caused by direct physical contact with cold or heat).
Omalizumab administration can result in anaphylaxis, a severe and potentially life-threatening allergic reaction. According to the FDA-approved labeling, this reaction can occur within minutes of injection but has also been documented to occur up to 24 hours or even days later. Because of this unpredictable timing, the first several doses must be administered in a clinical setting equipped to handle emergency allergic reactions. Patients are typically observed for 2 hours after the first three injections and for 30 minutes after subsequent injections. If you are approved for home administration, you must still be able to recognize the signs of anaphylaxis and have access to emergency treatment (epinephrine).
There are no medications that are strictly 'contraindicated' for use with omalizumab in the sense of causing a lethal chemical reaction. However, omalizumab should not be initiated in patients who are currently experiencing a severe, uncontrolled hypersensitivity reaction to any other monoclonal antibody until that reaction has completely resolved.
Omalizumab is strictly prohibited in the following circumstances:
In these situations, the healthcare provider must perform a careful risk-benefit analysis:
Omalizumab is classified by many clinicians as relatively safe for use during pregnancy when the benefits of asthma control outweigh the potential risks. Data from the EXPECT pregnancy registry, which monitored over 250 pregnant women with asthma treated with omalizumab, found no increased risk of major birth defects or miscarriage compared to women with similar asthma severity who did not take the drug.
Omalizumab is a very large protein molecule (approximately 145,000 Daltons). While it is present in human breast milk, the amount absorbed by the nursing infant is expected to be extremely low because the protein would likely be degraded in the infant's digestive tract.
Omalizumab is a humanized monoclonal antibody produced by recombinant DNA technology in a Chinese hamster ovary mammalian cell expression system. Its primary molecular target is the Cε3 domain of the heavy chain of free circulating human immunoglobulin E (IgE).
By binding to this specific site, omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FcεRI) on the surface of mast cells and basophils. This is the 'committing step' of the allergic cascade. By preventing this binding, omalizumab limits the degree of release of mediators (histamine, leukotrienes) of the allergic response. Additionally, the drug binds to IgE already bound to the low-affinity receptor (CD23) on B-cells and other inflammatory cells. A crucial secondary effect is that the reduction in free IgE leads to a significant down-regulation of FcεRI receptors on the surface of basophils and mast cells, further desensitizing the immune system to allergens.
Following a single subcutaneous dose, serum free IgE levels decrease by more than 96% within 1 hour. This suppression is maintained between doses. After discontinuation of the drug, free IgE levels return to pre-treatment levels over several months as the drug is cleared from the system. The time to reach maximum clinical effect for asthma or hives is typically 12 to 16 weeks, which corresponds to the time required for the down-regulation of receptors on inflammatory cells.
Common questions about Omalizumab-igec
Omalizumab is primarily used as a long-term maintenance treatment for moderate-to-severe persistent allergic asthma in patients who do not get enough relief from inhaled steroids. It is also FDA-approved to treat chronic spontaneous urticaria (chronic hives with no known cause) in adults and children 12 and older. Recently, it gained a significant new indication for reducing the risk of severe allergic reactions, including anaphylaxis, in people with IgE-mediated food allergies. Additionally, it is used to treat nasal polyps in adults when other nasal sprays haven't worked. It is important to note that it is not a rescue medication for sudden breathing problems.
The most common side effects reported by patients using omalizumab are injection site reactions, which can include pain, swelling, itching, and redness where the shot was given. Other frequent side effects include headaches, upper respiratory tract infections (like the common cold), and joint pain (arthralgia). In children, common side effects may also include fever and abdominal pain. Most of these symptoms are mild to moderate and tend to occur shortly after the injection. However, because of the risk of serious reactions, all side effects should be reported to your healthcare provider.
There is no known direct chemical interaction between alcohol and omalizumab that would make the drug less effective or more toxic. However, for many patients with asthma or chronic hives, alcohol can be a trigger that worsens their underlying condition. For example, some people experience 'alcohol-induced bronchoconstriction' or find that alcohol makes their hives more inflamed. While a moderate amount of alcohol is generally considered safe from a pharmacological standpoint, you should discuss your specific triggers with your doctor to ensure you aren't counteracting the benefits of the medication.
Current medical data, including the EXPECT pregnancy registry, suggests that omalizumab does not increase the risk of major birth defects or pregnancy complications. Because uncontrolled asthma can be very dangerous for both the mother and the developing baby (potentially causing low oxygen levels or premature birth), many doctors recommend continuing omalizumab during pregnancy if it is necessary for asthma stability. The drug does cross the placenta, especially in the later stages of pregnancy, so the baby will be exposed. You should have a detailed discussion with your obstetrician and allergist to weigh the risks and benefits for your specific situation.
Omalizumab is not a fast-acting medication. While it begins to lower the levels of free IgE in your blood within hours, the clinical benefits—such as fewer asthma attacks or reduced hives—usually take several weeks to become noticeable. Most healthcare providers evaluate the effectiveness of the treatment after 12 to 16 weeks of consistent dosing. This delay occurs because it takes time for the body to 'down-regulate' the receptors on mast cells and basophils. It is crucial to continue taking the medication exactly as prescribed, even if you do not feel an immediate difference in your symptoms.
You should not stop taking omalizumab without first consulting your healthcare provider. While there is no 'withdrawal' effect like you might see with some other medications, stopping the drug will cause your free IgE levels to gradually return to their original high levels. This usually results in the return of your asthma symptoms, hives, or food allergy sensitivity within a few weeks or months. If you need to stop the medication due to side effects or cost, your doctor will help you develop a transition plan to ensure your condition remains managed with alternative treatments.
If you miss a scheduled dose of omalizumab, you should contact your doctor's office or infusion center as soon as possible to reschedule the injection. Consistency is key to keeping your IgE levels suppressed and your symptoms under control. If you are self-administering at home and forget a dose, do not take a double dose to catch up. Instead, call your healthcare provider for guidance on when to take your next shot and how to adjust your future schedule. Keeping a calendar or setting phone reminders can help you stay on track with your 2-week or 4-week dosing cycle.
Weight gain is not a commonly reported side effect of omalizumab in clinical trials. Unlike oral corticosteroids (like prednisone), which are well-known for causing weight gain and changes in fat distribution, omalizumab is a biologic that targets a specific part of the immune system and does not typically affect metabolism or appetite. In fact, many patients find that by using omalizumab, they are able to reduce their use of steroids, which may actually help with weight management. If you notice significant or rapid weight changes while on this medication, you should discuss them with your doctor to rule out other causes.
Omalizumab is generally safe to take alongside most other medications, including standard asthma inhalers, antihistamines, and montelukast. It does not interact with the cytochrome P450 enzyme system, which is how many common drugs are processed by the liver. However, you should be cautious if you are using other 'biologic' medications for other conditions, as the combination hasn't been widely studied. Always provide your healthcare team with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are using to ensure there are no specific concerns for your individual health profile.
As of 2026, there are no 'generic' versions of omalizumab available. Because it is a complex biologic medication made in living cells, it cannot be copied exactly like a simple chemical pill. Instead, other companies may develop 'biosimilars.' While several biosimilars for omalizumab are in development and some may have reached the market recently, the brand name Xolair remains the most widely recognized version. Biosimilars are highly similar to the original product and have no clinically meaningful differences in safety or effectiveness. Your pharmacist or insurance provider can tell you if a lower-cost biosimilar version is available to you.
Other drugs with the same active ingredient (Omalizumab)
These side effects occur in a smaller percentage of the population but are still documented in clinical surveillance:
> Warning: Stop taking Omalizumab and call your doctor or emergency services immediately if you experience any of the following symptoms, as they may indicate a life-threatening reaction.
Long-term use of omalizumab (spanning several years) has generally been shown to be safe. However, because it modifies the immune system, long-term monitoring is required for:
Anaphylaxis Warning: Omalizumab carries an FDA Black Box Warning regarding the risk of anaphylaxis. Anaphylaxis has been reported to occur after the first dose of omalizumab, but also has occurred beyond 1 year after beginning regularly scheduled treatment. Because of the risk of anaphylaxis, healthcare providers should monitor patients closely for an appropriate period of time after omalizumab administration and be prepared to manage anaphylaxis that can be life-threatening. Patients should be informed of the signs and symptoms of anaphylaxis and be instructed to seek immediate medical care should symptoms occur.
Report any unusual symptoms or changes in your health to your healthcare provider immediately. Your doctor may ask you to carry an epinephrine auto-injector (EpiPen) as a precaution while you are on this medication.
Before and during treatment, several clinical assessments are necessary:
Omalizumab generally does not cause significant impairment of motor skills or cognitive function. However, some patients report dizziness or fatigue following an injection. It is recommended to see how you react to the medication before driving or operating heavy machinery, especially during the first 24 hours after a dose.
There are no known direct contraindications between omalizumab and alcohol consumption. However, alcohol can sometimes trigger or worsen asthma symptoms or hives in sensitive individuals. Discuss your alcohol intake with your doctor to ensure it does not interfere with your overall treatment goals.
Do not stop taking omalizumab without consulting your doctor. Discontinuing the drug will lead to a gradual rise in free IgE levels, and your symptoms (asthma, hives, or food allergy risk) will likely return to their baseline state within weeks to months. There is no known 'withdrawal syndrome,' but the loss of disease control can be dangerous, particularly in severe asthma. If you must stop, your doctor will provide a plan for monitoring your symptoms closely during the transition.
> Important: Discuss all your medical conditions, including any history of cancer or parasitic infections, with your healthcare provider before starting Omalizumab.
There are no known interactions between omalizumab and specific foods, such as grapefruit or dairy. However, it is vital to remember that for patients taking omalizumab for food allergies, the drug is not a license to eat the offending food. It is intended to protect against accidental exposure. You must continue to follow a strict food avoidance diet as directed by your allergist.
Formal interaction studies between omalizumab and herbal supplements have not been conducted. However, supplements that affect the immune system (such as echinacea or high-dose astragalus) could theoretically interfere with the drug's mechanism.
Omalizumab significantly interferes with the interpretation of Total Serum IgE levels.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter allergy medications and vitamins.
There is no known cross-sensitivity between omalizumab and small-molecule drugs (like aspirin or penicillin). However, patients who have had reactions to other monoclonal antibodies (such as rituximab or infliximab) may be at a slightly higher statistical risk for hypersensitivity reactions in general, though the drugs are structurally different. Always disclose any previous reactions to 'biologic' or 'protein-based' therapies to your doctor.
> Important: Your healthcare provider will evaluate your complete medical history, including any rare allergies to stabilizers used in vaccines or other injections, before prescribing Omalizumab.
Omalizumab has specific age-based approvals:
In clinical trials, patients aged 65 and older did not show significant differences in safety or efficacy compared to younger adults. However, geriatric patients often have a higher 'pill burden' (polypharmacy) and may have age-related declines in organ function.
Renal impairment is not expected to affect the clearance of omalizumab because it is not excreted by the kidneys. No dosage adjustment is recommended for patients with mild to severe kidney disease. However, these patients have not been studied specifically in clinical trials, so routine monitoring of general health is advised.
There is no specific data regarding omalizumab use in patients with hepatic impairment (e.g., Child-Pugh class A, B, or C). Since the liver's reticuloendothelial system is one of the sites of IgG catabolism, severe liver disease could theoretically slow the clearance of the drug, but this has not been clinically demonstrated. Use with caution in patients with significant liver dysfunction.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are planning to become pregnant or if you are managing multiple chronic health conditions.
| Parameter | Value |
|---|---|
| Bioavailability | ~62% (Subcutaneous) |
| Protein Binding | N/A (It is a protein itself) |
| Half-life | ~26 days |
| Tmax | 7–8 days |
| Metabolism | Reticuloendothelial system catabolism |
| Excretion | Biliary/Endothelial degradation (Minimal Renal) |
Omalizumab is the first-in-class Anti-IgE antibody. While other biologics exist for asthma (such as IL-5 inhibitors like Mepolizumab), omalizumab is unique because it targets the IgE molecule itself rather than specific cytokines. It is often grouped within the broader category of 'Biological Response Modifiers' or 'Immunomodulators.'